Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform

PUBT · 2d ago
Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform
  • Cellectis outlined 4 ongoing allogeneic CAR-T clinical trials, including 2 pivotal Phase 2 studies and 2 Phase 1 studies.
  • Cash position of USD 169 million as of June 30, 2026; expected runway into Q4 2027.
  • Lasme-cel pivotal Phase 2 first interim analysis expected in Q4 2026; eti-cel Phase 1 full dataset expected in Q4 2026.
  • Presentation highlighted TALEN gene-editing platform positioning on safety, precision, efficiency, versatility.
  • Manufacturing footprint centered on Paris, France, and Raleigh, North Carolina, supporting end-to-end in-house production.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.